124 related articles for article (PubMed ID: 31323236)
1. New antibody-based prevention and treatment options for influenza.
Sedeyn K; Saelens X
Antiviral Res; 2019 Oct; 170():104562. PubMed ID: 31323236
[TBL] [Abstract][Full Text] [Related]
2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
3. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
[TBL] [Abstract][Full Text] [Related]
5. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
7.
Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
[TBL] [Abstract][Full Text] [Related]
8. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.
Wang TT; Tan GS; Hai R; Pica N; Petersen E; Moran TM; Palese P
PLoS Pathog; 2010 Feb; 6(2):e1000796. PubMed ID: 20195520
[TBL] [Abstract][Full Text] [Related]
9. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
10. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.
Tan GS; Krammer F; Eggink D; Kongchanagul A; Moran TM; Palese P
J Virol; 2012 Jun; 86(11):6179-88. PubMed ID: 22491456
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
[TBL] [Abstract][Full Text] [Related]
12. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
[TBL] [Abstract][Full Text] [Related]
13. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
14. Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it.
Wang W; Vassell R; Song HS; Chen Q; Keller PW; Verma S; Alvarado-Facundo E; Wan H; Schmeisser F; Meseda CA; Weir JP; Weiss CD
PLoS One; 2019; 14(9):e0222436. PubMed ID: 31513662
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
[TBL] [Abstract][Full Text] [Related]
16. An epitope on the stem region of hemagglutinin of H1N1 influenza A virus recognized by neutralizing monoclonal antibody.
Yan L; Wang H; Sun L; Liu Y; Sun J; Zhao X; Li Y; Xie X; Hu J
Biochem Biophys Res Commun; 2019 Oct; 518(2):319-324. PubMed ID: 31421820
[TBL] [Abstract][Full Text] [Related]
17. One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I.
Saelens X
EBioMedicine; 2016 Mar; 5():16-7. PubMed ID: 27077102
[No Abstract] [Full Text] [Related]
18. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
Cho A; Wrammert J
Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
[TBL] [Abstract][Full Text] [Related]
20. Highly conserved protective epitopes on influenza B viruses.
Dreyfus C; Laursen NS; Kwaks T; Zuijdgeest D; Khayat R; Ekiert DC; Lee JH; Metlagel Z; Bujny MV; Jongeneelen M; van der Vlugt R; Lamrani M; Korse HJ; Geelen E; Sahin Ö; Sieuwerts M; Brakenhoff JP; Vogels R; Li OT; Poon LL; Peiris M; Koudstaal W; Ward AB; Wilson IA; Goudsmit J; Friesen RH
Science; 2012 Sep; 337(6100):1343-8. PubMed ID: 22878502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
